Background and purpose: Improved biomarkers are needed to facilitate clinical decision-making and as surrogate endpoints in clinical trials in multiple sclerosis (MS). We assessed whether neurodegenerative and neuroinflammatory markers in cerebrospinal fluid (CSF) at initial sampling could predict disease activity during 2 years of follow-up in patients with clinically isolated syndrome (CIS) and relapsing-remitting MS. Methods: Using multiplex bead array and enzyme-linked immunosorbent assay, CXCL1, CXCL8, CXCL10, CXCL13, CCL20, CCL22, neurofilament light chain (NFL), neurofilament heavy chain, glial fibrillary acidic protein, chitinase-3-like-1, matrix metalloproteinase-9 and osteopontin were analysed in CSF from 41 patients with CIS or relapsing-remitting MS and 22 healthy controls. Disease activity (relapses, magnetic resonance imaging activity or disability worsening) in patients was recorded during 2 years of follow-up in this prospective longitudinal cohort study. Results: In a logistic regression analysis model, NFL in CSF at baseline emerged as the best predictive marker, correctly classifying 93% of patients who showed evidence of disease activity during 2 years of follow-up and 67% of patients who did not, with an overall proportion of 85% (33 of 39 patients) correctly classified. Combining NFL with either neurofilament heavy chain or osteopontin resulted in 87% overall correctly classified patients, whereas combining NFL with a chemokine did not improve results. Conclusions: This study demonstrates the potential prognostic value of NFL in baseline CSF in CIS and relapsing-remitting MS and supports its use as a predictive biomarker of disease activity.
Introduction
Multiple sclerosis (MS) is a chronic disease characterized by inflammation and degeneration of the central nervous system (CNS). The prognosis is highly variable and magnetic resonance imaging (MRI), although being a very important diagnostic and follow-up tool, is not an optimal prognostic tool. Conventional MRI data, like T2 lesion load, correlate poorly with the clinical disease manifestations and disease progression [1] , although lesion load and brain atrophy have been shown to predict long-term disability [2] . Hence, there is a need for non-MRI biomarkers in MS to aid individualized pharmacological treatment early in the disease course. The ample research on MS biomarkers has recently been reviewed [3] [4] [5] . Neurofilament light chain (NFL) in cerebrospinal fluid (CSF) has been reported to correlate with long-term (8-20 years) prognosis [6] and treating MS with fingolimod and natalizumab has been shown to decrease NFL levels [7, 8] . It is currently debated whether or not it is appropriate to measure NFL in CSF when monitoring response to treatment in order to guide clinical decisions on therapy [9, 10] . There are complex relationships and overlaps between neuroinflammation and neurodegeneration in MS. Inflammatory biomarkers and markers of axonal damage in CSF have been shown to correlate in different combinations in different types of MS [11] . However, results are inconsistent and there is no biomarker that is entirely specific for MS [4] .
In this study, we evaluated a broad panel of neurodegenerative and inflammatory markers. NFL, neurofilament heavy chain (NFH) and glial fibrillary acidic protein (GFAP) were included as established markers of axonal degeneration [12] and astrogliosis [4] , respectively. Chitinase-3-like-1 protein (CHI3L1) is a marker of activated astrocytes and microglia [4] , and matrix metallopeptidase-9 (MMP-9) is a matrixdegrading enzyme. Both CHI3L1 and MMP-9 have been suggested as surrogate markers of disease activity in MS [13, 14] . Osteopontin (OPN) is a multipotent molecule involved in activation and polarization of T-cells [15] and has been reported to be increased in CSF from patients with MS [16] . Chemokines are attractive biomarkers because they recruit specific inflammatory cells that reflect the ongoing type of inflammation. Chemokines are also generally present at higher concentrations than cytokines and are therefore easier to reliably measure in plasma and CSF. In MS, CXCL13 (a B-cell chemoattractant) has been reported to be elevated in CSF [17] and associated with disease exacerbations and unfavorable prognosis [18] . Chemokines recruit different settings of Th subsets and they therefore represent and can be used as markers of Th1 (CXCL1, CXCL10), Th2 (CCL22) and Th17 (CXCL8, CCL20) immunity [19] .
'No evidence of disease activity' (NEDA) is increasingly used as a comprehensive measure of treatment response in MS and the combination of no relapses, no brain MRI activity (new or enlarging T2 lesions or gadolinium-enhancing lesions) and no sustained disability worsening is often called NEDA-3. Expanding the NEDA concept to NEDA-4, where brain volume loss is added, or NEDA-5, where a biomarker in CSF or serum is also added, is currently being discussed [20] .
This study aimed to assess whether concentrations of neurodegenerative and neuroinflammatory markers in CSF and plasma at baseline were able to predict disease activity during 2 years of follow-up in a longitudinal cohort of patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS), and to identify the best prognostic markers in our material. We report that NFL in CSF at baseline emerged as the best predictive marker, correctly classifying 85% of patients with regard to NEDA-3 or not NEDA-3 during 2 years of follow-up. Combining NFL with NFH or OPN resulted in 87% overall correctly classified patients, whereas combining NFL with any of the chemokines analyzed did not improve results.
Materials and methods

Patients and controls
Forty-one patients with CIS or RRMS were consecutively enrolled in a prospective longitudinal cohort study of CIS and newly diagnosed MS at the Department of Neurology, University Hospital Link€ oping, Sweden. All patients fulfilled the revised McDonald criteria from 2010 [21] for CIS or MS. Patients underwent clinical neurological examination including expanded disability status scale (EDSS), peripheral blood and CSF sampling, and MRI at baseline and at 2 years of follow-up. Patients received immunomodulatory treatment according to Swedish clinical practice. Patient characteristics are shown in Table 1 .
For peripheral blood and CSF, 22 age-and sexmatched healthy controls (HCs) were recruited from healthy blood donors. HCs were free from past and current neurological and autoimmune disease, and their clinical neurological examinations were normal as were routine findings in CSF (Table 1) . No medication, except oral contraceptive pills, was allowed in HCs.
Ethics statement
The study was approved by The Regional Ethics Committee in Link€ oping and written informed consent was obtained from all participants.
Cerebrospinal fluid and plasma analyses
All CSF sampling was carried out by the same neurologist (I.H.) and CSF was always collected at 08.00-12.00 hours. Plasma samples were collected directly after CSF collection. One aliquot of the CSF sample was used for cell counting, CSF:serum albumin ratio, IgG index, IgG synthesis index and isoelectric focusing, all according to clinical routines performed at the Department of Clinical Chemistry. Within 1 h, the remaining CSF was centrifuged (300 g for 10 min) and the supernatant was aliquoted and immediately frozen and stored at À70°C.
Plasma and CSF samples were analyzed for cytokine and chemokine concentrations with a multiplex bead assay ( P values from chi-square test for sex distribution and oligoclonal bands, and from Mann-Whitney U-test for independent samples for age and cerebrospinal fluid (CSF) data. CIS, clinically isolated syndrome; DMT, disease-modifying treatment; EDSS, expanded disability status scale; NA, not applicable; RRMS, relapsing-remitting multiple sclerosis. Data are given as median (interquartile range). Disease duration refers to time from first symptom suggestive of demyelinating disease.
data analysis. The detection limits were 16 pg/mL for CXCL1, CXCL10 and CCL22, 3.2 pg/mL for CXCL8, 3.9 pg/mL for CXCL13 and 9.8 pg/mL for CCL20. The CSF NFL concentrations were measured using the NFL assay according to the manufacturer's instructions (UmanDiagnostics, Umea, Sweden). CSF NFH concentrations were measured using the phosphorylated NFH (Human) ELISA Kit according to the manufacturer's instructions (Abnova, Taipei City, Taiwan). CSF MMP-9 concentrations were measured using the Human MMP-9 Base Kit according to the manufacturer's instructions (Meso Scale Discovery, Rockville, MD, USA). CSF GFAP concentrations were measured using an in-house enzyme-linked immunosorbent assay (ELISA) as previously described [22] . CSF CHI3L1 and OPN concentrations were measured using commercially available ELISAs (R&D Systems, Inc., Minneapolis, MN, USA). The lower limits of quantification for the NFH and MMP-9 assays were 31.2 and 122 pg/mL, respectively. For the other analytes, all samples had concentrations within the quantifiable range of the assay. All measurements were performed in one round of experiments using one batch of reagents by board-certified laboratory technicians who were blinded to clinical information. Intra-assay coefficients of variation were below 15%.
Magnetic resonance imaging
All MRI examinations were performed on a 1.5 T Achieva MRI system (Philips Healthcare, Best, The Netherlands). The examination protocol is presented in the Supporting Information. All MRI examinations were reviewed by the same neuroradiologist.
Statistics
Statistical analyses were performed using SPSS for Windows, version 23. Non-parametric tests were primarily used due to the non-Gaussian distribution. The Mann-Whitney U-test was used to compare two groups and the Kruskal-Wallis test followed by the Mann-Whitney U-test was used to compare multiple study groups. Values below the detection limit were assigned half the value of the detection limit and included in statistical tests. Because of multiple testing, a stringent P value of <0.01 was considered to be significant in Mann-Whitney U-tests, whereas P < 0.05 was used as cut-off in Kruskal-Wallis tests to allow post-hoc Mann-Whitney testing. All P values were based on two-tailed statistical tests. Non-parametric bivariate correlation analysis (Spearman) was used when investigating possible association between NFL and other parameters. Logistic regression was used when investigating whether NFL alone or in combination with other variables could predict disease activity. Receiver-operating characteristic (ROC) curves were derived from logistic regression to investigate the discriminatory power of NFL between patients and controls and between patients with and without disease activity during follow-up.
Results
Neurodegenerative and neuroinflammatory markers in patients at baseline and in healthy controls
At baseline, when all 41 patients were untreated, CSF levels of NFL, NFH, CHI3L1, MMP-9, CXCL1, CXCL8, CXCL10, CXCL13 and CCL22 were significantly higher in patients than in HCs, whereas GFAP and OPN did not differ between patients and HCs ( Table 2 ). CCL20 levels in CSF were below the detection level in both patients and HCs. CXCL13 and CCL22 in CSF were below the detection level in HCs. Patients and HCs did not differ in plasma levels in any of the cytokines or chemokines.
The patients were also stratified by diagnosis (CIS/ RRMS) and relapse status (see Data S1, Data S2, Tables S1 and S2). It is of note that NFL in CSF at baseline was not significantly higher in patients with RRMS than with CIS, or in patients with relapse than in relapse-free patients, regardless of whether time from onset of relapse was within 2 months (Table S2) or within 1 or 3 months (data not shown) before CSF collection.
The NFL at baseline did not correlate with patient age or EDSS (data not shown), whereas there were weak correlations with mononuclear cells in CSF at baseline (Spearman 0 s rho, 0.41; P = 0.01) and total number of T2 lesions in the brain at baseline (Spearman 0 s rho, 0.38; P = 0.02), and a stronger correlation with number of new lesions in brain MRI during 2 years of follow-up (Spearman 0 s rho, 0.60; P < 0.001). There were moderate to strong positive correlations between several of the neurodegenerative and neuroinflammatory markers in CSF at baseline ( Table 3 ).
Considering that NFL performed well in predicting disease activity in the patient group (see below), we evaluated how well NFL at baseline discriminated between patients and HCs. With logistic regression analysis based on NFL, 71% of patients (29/41) and 82% of HCs (18/22) could be correctly classified, with an overall correctly classified proportion of 75% (47/ 63 individuals). Sensitivity and specificity for different NFL values were determined using ROC curve analysis (Fig. 1a ). An NFL value ≥450 ng/L captured 71% of patients and had a specificity of 86%.
Neurodegenerative and neuroinflammatory markers at baseline in relation to disease activity during followup
Patients who showed no relapses, no brain MRI activity (no new or enlarging T2 lesions or gadolinium-enhancing lesions) and no sustained disability worsening (EDSS progression) were classified as showing NEDA (n = 12). Patients with relapses, brain MRI activity or sustained disability worsening were classified as showing evidence of disease activity (EDA) (n = 27).
The CSF levels of NFL, NFH, GFAP, OPN, CXCL10, CXCL13 and CCL22 at baseline were significantly lower in the NEDA group than in the EDA group at 2 years of follow-up (Table 4) . Thirty-nine patients could be evaluated at 2 years (one patient did not undergo an MRI due to pregnancy and one patient had left the study). Data on neurodegenerative and neuroinflammatory markers in CSF at baseline in relation to disease activity during 2 years of follow-up are visualized in Fig. 2 and Table S3 .
The predictive value of baseline neurodegenerative and neuroinflammatory markers in relation to disease Data are given as magnitude of correlation coefficients (r) with significant correlations in bold. P values from bivariate non-parametric correlation analyses (Spearman): *P < 0.01, **P < 0.001. CHI3L1, chitinase-3-like-1 protein; GFAP, glial fibrillary acidic protein; MMP-9, matrix metallopeptidase-9; NFH, neurofilament heavy chain; NFL, neurofilament light chain; OPN, osteopontin. Concentrations are given as median (interquartile range). CHI3L1, chitinase-3-like-1 protein; CSF, cerebrospinal fluid; GFAP, glial fibrillary acidic protein; MMP-9, matrix metallopeptidase-9; NFH, neurofilament heavy chain; NFL, neurofilament light chain; OPN, osteopontin; P, plasma; UD, under detection limit. P values from Mann-Whitney U-test for independent samples, patients compared with HCs. Significant differences are in bold.
activity during follow-up was evaluated with logistic regression, as shown in Table 4 . We found that NFL performed best at predicting disease activity status at 2 years, correctly classifying 93% of patients with EDA (25/27) and 67% of patients with NEDA (8/12). The overall correctly classified proportion of patients was 85% (33/39) (Nagelkerke R 2 , 0.44). We then combined NFL with the other markers one by one. The only combinations that yielded a slightly higher overall percentage of correctly classified patients (87%, 34/ 39 patients) were NFL+NFH and NFL+OPN (Table 4) . Combining NFL with both NFH and OPN did not improve results further.
An ROC curve for NFL at baseline in relation to disease activity during 2 years of follow-up is shown in Fig. 1b . With a cut-off value of ≥450 ng/L for NFL, 93% of patients showing disease activity were identified and the specificity was 62%.
Within the CIS group (n = 19) we found higher NFL levels in CSF at baseline in patients converting to RRMS (n = 9; median NFL, 2332 ng/L; interquartile range, 1348-2810 ng/L) during 2 years of followup compared with patients who did not convert to RRMS (n = 10; median NFL, 245 ng/L; interquartile range, 190-747 ng/L) (P = 0.001). With logistic regression, NFL correctly classified 78% of converters (7/9) and 90% of non-converters (9/10). The overall correctly classified proportion of patients was 84% (16/19) (Nagelkerke R 2 , 0.67). An ROC curve for NFL at baseline in relation to conversion from CIS to RRMS during 2 years of follow-up is shown in Fig. 1c . With a cut-off value of ≤500 ng/L for NFL, 89% of patients with CIS not converting to RRMS were identified and the specificity was 70%.
Discussion
In the present study, we examined a prospective longitudinally followed cohort of patients with CIS and newly diagnosed MS to evaluate a broad set of both established and non-established markers of neurodegeneration and neuroinflammation as potential Prediction of disease activity. NFL in CSF at baseline and separation of patients with (n = 27) and without (n = 12) evidence of disease activity during 2 years of follow-up. AUC is 85%. (c) Prediction of conversion from clinically isolated syndrome (CIS) to relapsingremitting multiple sclerosis (RRMS). NFL in CSF at baseline in patients with CIS (n = 19) and separation of patients not converting to RRMS during 2 years of follow-up (n = 10) and patients converting to RRMS during 2 years of follow-up (n = 9). AUC is 92%. CHI3L1, chitinase-3-like-1 protein; EDA, patients with evidence of disease activity during 2 years of follow-up {relapses, brain magnetic resonance imaging (MRI) activity [new or enlarging T2 lesions or gadolinium (Gd)-enhancing lesions] or disability worsening}; GFAP, glial fibrillary acidic protein; MMP-9, matrix metallopeptidase-9; NEDA, patients with no evidence of disease activity during 2 years of follow-up [no relapses, no brain MRI activity (new or enlarging T2 lesions or Gdenhancing lesions) and no disability worsening]; NFH, neurofilament heavy chain; NFL, neurofilament light chain; OPN, osteopontin.
prognostic markers of disease activity. Importantly, we show that NFL in CSF predicted whether patients would show signs of disease activity during 2 years of follow-up. Considering the heterogeneity in MS, prediction of disease activity using fluid biomarkers would be of great value in decision-making about treatment strategy.
The CSF levels of NFL in patients with CIS have been reported to be an independent prognostic marker for conversion from CIS to MS [23] [24] [25] , to correlate with MS severity score during long-term follow-up in MS [6] and to decrease on treatment [8] . To our knowledge, this is the first study to demonstrate that NFL at baseline is a strong predictor of disease Figure 2 Neurodegenerative and neuroinflammatory markers at baseline in healthy controls and in patients subgrouped by disease activity during 2 years of follow-up. Concentrations are given in pg/mL. Lines show median and interquartile range. **P ≤ 0.01 (MannWhitney U-test for independent samples), ***P < 0.001 (Mann-Whitney Utest for independent samples), ns P > 0.01
(Mann-Whitney U-test for independent samples). Healthy controls (HCs) (n = 22 activity in the comprehensive form of NEDA-3 status during 2 years of follow-up in CIS and newly diagnosed MS. We also confirmed that CSF levels of NFL predicted conversion from CIS to MS. Thus, based on our and previous data, NFL in CSF emerges as a useful prognostic biomarker of disease activity. It has been shown that exposure to room temperature or repetitive thawing does not influence measurement of NFL concentrations [26] , which is of great value for a potential biomarker. NFL in CSF at baseline did not correlate with patient age at baseline in our study and we believe that this is due to the relatively young age of most patients in the cohort, as otherwise age should be taken into account when evaluating NFL levels [27] . We also evaluated several other suggested CSF biomarkers related to the process of CNS tissue damage (NFH, GFAP, CHI3L1 and MMP-9) and CNS inflammation (CXCL1, CXCL8, CXCL10, CXCL13 and CCL22) but, in our setting, NFL in CSF stood out as the most useful prognostic biomarker of NEDA.
After identifying NFL at baseline as the sole marker with the highest ability to predict disease activity after 2 years, we tested whether combining NFL with other markers could add to the predictive value. Although chemokines have been increasingly recognized as potential biomarkers, in our study the combining of NFL with a chemokine did not improve results. Combining NFL with NFH or OPN yielded a slightly higher proportion of correctly predicted patients. However, no conclusions regarding additional predictive value of these markers can be drawn from this study. NFH has previously not been associated with prediction of disease activity and, in our cohort, NFH alone did not predict NEDA-3 as well as NFL. However, as NFH was recently suggested to predict long-term brain atrophy in MS [28] , it is a marker that should be considered in further prognostic studies. In previous studies of OPN in MS, it was associated with ongoing disease activity [16] , but could also predict time to conversion from optic neuritis to MS, although it was outperformed by CHI3L1 in that setting [25] . In our study, OPN levels in CSF did not differ between patients and controls at baseline, and were not increased at time of relapse. However, OPN may carry prognostic information. Interestingly, OPN was recently shown to be part of a module of dysregulated genes in activation of T helper cells in MS [29] .
A strength of this study is that the control group consisted of sex-and age-matched healthy individuals, not patients with 'other neurological diseases' or patients examined due to a suspicion of neurological disease but without clinical findings indicating a CNS disorder. Another strength is that the patient group consisted of patients with well-characterized CIS and MS who were examined and thoroughly followed-up by the same neurologist in a standardized way. NFL levels did not differ between patients in relapse and patients not in relapse at the time of CSF collection in our study. Data on NFL levels in relation to relapse status in other studies are inconsistent [23, 30] , possibly because of differences in sample size and patient selection. Our finding of similar levels of NFL irrespective of relapse implies a positive quality as a clinical biomarker. A limitation of our study is the small sample size when stratifying into subgroups. However, data were clear and consistent, and we used a stringent statistical approach to compensate for multiple testing.
The present study was designed to detect short-term effects, i.e. disease activity during 2 years of follow-up, and future studies will address biomarkers in relation to long-term outcome including development of atrophy. It is of note that none of the inflammatory markers in plasma were increased in patients compared with controls, showing that CSF sampling is necessary to mirror the CNS inflammation. Regarding neuronal markers, serum NFL was not available in the present study, but it will be interesting to see whether serum levels of NFL assessed with super-sensitive assays [31] can also be used as biomarkers in MS.
In conclusion, we found that the CSF levels of NFL at baseline were able to predict disease activity during 2 years of follow-up in CIS and RRMS. The finding supports the use of NFL in CSF as a biomarker. The use of biomarkers in clinical practice can help us to individualize treatment early in the disease course. unrestricted research grants from Biogen and Novartis, honoraria for lectures from Biogen and Genzyme, and for advisory boards from Roche and Novartis. C.D. has received honoraria for lectures from Biogen, Teva, Genzyme and Novartis, and for advisory boards from Roche, Novartis and Biogen. K.B. and H.Z. are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. K.B. has served as a consultant or on advisory boards for IBL International, Roche Diagnostics, Eli Lilly, Fujirebio Europe and Novartis.
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